PTC Therapeutics, Inc.

PTCT

$70.20

-0.41%-$0.29

High—

Low—

52W High-22.7%

Rel. vol—

Interval

Range70m

Volume—SMA5SMA10

—

AI analysis

PTC Therapeutics, Inc. is showing mixed intraday momentum with consolidation near key moving averages and heightened sensitivity to liquidity shifts.

Upside confirmation strengthens on sustained reclaim above short-term trend anchors.
Breakdown risk rises if support fails with accelerating sell volume.
Relative strength versus sector peers remains neutral-to-slightly positive.

Latest indicator snapshot

Live technical and fundamental context, tuned for quick reads.

SMA5

$70.54

5-period simple moving average

SMA10

$70.62

10-period simple moving average

SMA20

$70.71

20-period simple moving average

SMA50

—

50-period simple moving average

EMA5

$70.47

5-period exponential moving average

EMA10

$70.58

10-period exponential moving average

EMA20

$70.69

20-period exponential moving average

DEMA20

$70.56

Double exponential moving average

Fibonacci

Retracement

Retracement levels

VWAP

$70.90

Volume weighted average price

MACD

-0.107

Signal -0.060

RSI(14)

23.0

Relative strength oscillator

OBV

-3.08K

On-balance volume

StochRSI

23.0 / 23.0

Fast oscillator pair

BBands Low

$70.39

Lower band

BBands Mid

$70.71

Middle band

BBands High

$71.03

Upper band

Market Cap

5.96B

Company size

P/E Ratio

0.00

Valuation multiple

EV / EBITDA

25.09

Enterprise value multiple

ROE

-7740.0%

Return on equity

ROA

2.5%

Return on assets

Operating Margin

41.3%

Operating efficiency

Net Margin

-3.8%

Bottom-line profitability

Current Ratio

—

Short-term liquidity

Debt / Equity

—

Balance-sheet leverage

Dividend Yield

0.0%

Income yield

FCF Yield

—

Free cash flow yield

Beta

0.55

Market sensitivity

52W High

$90.87

52-week peak

52W Low

$56.51

52-week trough

Supply Chain of PTCT

Upstream / Downstream / Proxies

Upstream

Alcami CorporationAldevron (Danaher Corporation)NYSE:DHRMassBiologics (University of Massachusetts Medical School)Roche/Genentech (F. Hoffmann-La Roche AG)SIX:ROGIonis Pharmaceuticals (via Akcea Therapeutics)NASDAQ:IONSMerck KGaA (MilliporeSigma)ETR:MRKThermo Fisher Scientific (Patheon)NYSE:TMOComplete Pharma Holdings, LLC

Downstream

Novartis AGNYSE:NVSOrsini Specialty PharmacyOptum Frontier Therapies (UnitedHealth Group)NYSE:UNHRareMed SolutionsRoyalty Pharma plcNASDAQ:RPRXGenentech (Roche Group)SIX:ROGAkcea Therapeutics (Ionis affiliate)NASDAQ:IONS

Proxies

Royalty Pharma plcNASDAQ:RPRX Ionis Pharmaceuticals, Inc.NASDAQ:IONS Sarepta Therapeutics, Inc.NASDAQ:SRPT BioMarin Pharmaceutical Inc.NASDAQ:BMRN

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer